Artesunate before surgery for colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a drug called artesunate before surgery can improve outcomes for people with stage II or III colorectal cancer. It aims to see if it is safe and effective, and may help shrink the tumor or reduce the chance of it coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You need a diagnosis of stage II or III colorectal cancer (including high-grade dysplasia with signs of invasive cancer).
- Your cancer must be scheduled for surgical removal, and you should not need chemotherapy or radiation before surgery.
- You need to have a certain level of health: adequate blood counts, kidney function, and liver function.
- Your weight must be between 52 kg and 110 kg.
- You should not have a history of hearing or balance problems, immunosuppression, or other cancers in the last 2 years (except certain skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests treatments given before surgery for colorectal cancer that has not spread. The goal is to shrink the tumor and improve surgical outcomes. It may be an option for patients with stage II or III colorectal cancer who have not had prior treatment.
This trial tests whether giving chemotherapy before surgery can improve outcomes for patients with colon cancer that has not spread to other parts of the body. The treatment aims to shrink the tumor and reduce the chance of the cancer coming back.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests a combination of drugs before surgery for locally advanced colorectal cancer. The goal is to see if this treatment shrinks the tumor and improves surgical outcomes.
This trial tests two immunotherapy drugs (ADG126 and pembrolizumab) given before surgery for locally advanced colorectal cancer that hasn't spread. It aims to shrink tumors and improve outcomes.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
Hear when a new Bowel Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.